Megestrol and embryonic extracts in the treatment of advanced hepatocellular carcinoma: A prospective randomized trial in the pre-sorafenib era

Hepatology Research

Volumn 40, Issue 2, 2010, Pages 153-160

  Giacomin, Anna ^a   Sergio, Adriana ^a   Vanin, Veronica ^a   Tartaro, Pietro ^a   Paccagnella, Daniela ^b   Mazzucco, Mauro ^c   Farinati, Fabio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b S ANTONIO HOSPITAL   (Italy)

^c Internal Medicine Unit   (Italy)

Author keywords

Advanced stages; Hepatocellular carcinoma; Megestrol; Stem cell factors; Treatment

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; MEGESTROL; SORAFENIB; STEM CELL FACTOR;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

EID: 77954379927     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00588.x     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005, 55:74-108.
2. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008, 48(1):S20-37. Suppl
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Hepatology 2005, 42:1208-36.
4. Llovet JM, Ricci S, Mazzaferro V. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-90.
5. Cheng A, Kang Y, Chen Z. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol 2008, 26. Suppl. abstract 4509
6. Villa E, Ferretti I, Grottola A. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 2001, 84:881-5.
7. Livraghi T, Meloni F, Frosi A. Treatment with stem cell differentiation stage factors of intermediate-advanced hepatocellular carcinoma: an open randomized clinical trial. Oncol Res 2005, 15:399-408.
8. Biava PM, Fiorito A, Negro C, Mariani M. Effects of treatment with embryonic and uterine tissue homogenates on Lewis lung carcinoma development. Cancer Lett 1988, 41:265-70.
9. Biava PM, Bonsignorio D, Hoxha M. Life protecting factor (LPF): an anticancer low molecular weight fraction isolated from pregnant uterine mucosa during embryo organogenesis. J Tumor Marker Oncol 2000, 15:223-33.
10. Biava PM, Bonsignorio D, Hoxha M. Cell proliferation curves of different human tumor lines after in vitro treatment with zebrafish embryonic extracts. J Tumor Marker Oncol 2001, 16:195-201.
11. Biava PM, Bonsignorio D, Hoxha M. Mother-embryo cross-talk: the anticancer substanced produced by mother and embryo during cell differentiation. A review of experimental data. J Tumor Marker Oncol 2002, 17:55-8.
12. Therasse P, Arbuck SG, Eisenhauer EA. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-16.
13. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006, 42:1031-9.
14. Thomas MB, O'Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol 2008, 15:1008-14.
15. Abou-Alfa GK. Hepatocellular carcinoma: molecular biology and therapy. Semin Oncol 2006, 33(11):S79-83. Suppl.
16. Pastorelli D, Cartei G, Zustovich F. Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature. Ann Oncol 2006, 17(5):153-7. Suppl.
17. Di Maio M, Daniele B, Pignata S. Is human hepatocellular carcinoma a hormone-responsive tumor? World J Gastroenterol 2008, 14:1682-9.
18. Farinati F, Salvagnini M, De Maria N. Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. J Hepatol 1990, 11:297-301.
19. Tamoxifen in treatment of hepatocellular carcinoma: a randomized controlled trial. Lancet 1998, 352:17-20. CLIP Group (Cancer of the Liver Italian Programme)
20. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-42.
21. Nowak AK, Stockler MR, Chow PK, Findlay M. Use of tamoxifen in advanced stage hepatocellular carcinoma. A systematic review. Cancer 2005, 103:1408-14.
22. Villa E, Colantoni A, Grottola A. Variant estrogen receptors and their role in liver disease. Mol Cell Endocrinol 2002, 193:65-9.
23. Farinati F, Gianni S, De Giorgio M, Fiorentini S. Megestrol treatment in patients with hepatocellular carcinoma. Br J Cancer 2001, 85:1606-8.
24. Kouroumalis E, Skordilis P, Thermos K. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998, 42:442-7.
25. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K. The role of sandostatin LAR in treating patients with advanced hepatocellular carcinoma. Hepatogastroenterology 2002, 49:1245-50.
26. Samonakis DN, Moschandreas J, Arnaoutis T. Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep 2002, 9:903-7.
27. Becker G, Allgaier HP, Olschewski M, Zähringer A, Blum HE. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007, 45:9-15.
28. Cebon J, Gastro-intestinal A. Trials group (AGITG) and Ag0001H Investigators. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer 2006, 95:853-61.
29. Yuen MF, Poon RT, Lai CL. A randomised placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002, 36:687-91.
30. Farinati F, Sergio A, Baldan A, Zucchetta P, Corleto VD. Octreotide and hepatocellular carcinoma. Br J Cancer 2007, 96:1778-9.
31. Sieghart W, Fuereder T, Schmid K. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 2007, 83:425-32.
32. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006, 11:790-800.
33. Thomas MB, Chadha R, Glover K. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007, 110:1059-67.
34. Farinati F, Marino D, De Giorgio M. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006, 101:524-32.